Revvity has expanded its alliance with Genomics England to further collaborate on the Generation Study. Under the new contract, Revvity will now also provide DNA sequencing services to help screen newborns for rare genetic conditions.
This expanded relationship builds upon the existing partnership for DNA extraction services. Revvity will now be able to provide an integrated end-to-end solution with a localised laboratory facility, which will allow for accelerated extraction and sequencing services to advance the screening process for these rare conditions.
The Generation Study, a research project spearheaded by Genomics England in partnership with the National Health Service, is a landmark national initiative aimed at screening up to 100,000 newborns for more than 200 rare genetic disorders. The findings will help inform future decisions on using whole genome sequencing (WGS) in newborn screening. Proactive genomic screening could help healthcare professionals identify risks for paediatric-onset conditions sooner, enabling earlier interventions and personalized care.
“It is an honour to enhance our collaboration with Genomics England as we align to expand access to genomic sequencing in England. Our complete solution and localised laboratory facility help us deliver timely and reliable sequencing data in support of this critical programme that strengthens newborn health,” stated Dr Madhuri Hegde, Revvity’s Senior Vice President and Chief Scientific Officer. “Revvity’s expansive global laboratory network combined with our next-generation sequencing solutions and workflows for newborn screening uniquely positions us to lead this and similar initiatives, setting a standard for future programmes.”
“This collaboration is an important step forward in our mission to generate evidence on the use of genomic sequencing in newborn screening, added Dr Ellen Thomas, chief medical officer at Genomics England. “By working with Revvity as one of our sequencing partners for the Generation Study, we can integrate sequencing alongside extraction, streamlining the process, and generating results more efficiently, helping families get answers and access to care sooner.”